Laurus Labs rises on acquiring equity shares in KRKA
Laurus Labs is currently trading at Rs. 578.65, up by 5.20 points or 0.91% from its previous closing of Rs. 573.45 on the BSE.
The scrip opened at Rs. 574.95 and has touched a high and low of Rs. 586.45 and Rs. 573.55 respectively. So far 8203 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 646.25 on 07-Feb-2025 and a 52 week low of Rs. 372.20 on 20-Mar-2024.
Last one week high and low of the scrip stood at Rs. 586.45 and Rs. 553.05 respectively. The current market cap of the company is Rs. 31203.85 crore.
The promoters holding in the company stood at 27.60%, while Institutions and Non-Institutions held 38.30% and 34.10% respectively.
Laurus Labs has invested Rs 83.30 crore and acquired 83,300,000 equity shares of KRKA Pharma (KRKA) (a joint venture of the Company) a at face value of Rs 10 each by way of rights issue.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C.
